A simulation study of approaches for handling disease progression in dose-finding clinical trials-Reference-Cited by-同舟云学术

A simulation study of approaches for handling disease progression in dose-finding clinical trials

Published:2020-09-15 Issue:2 Volume:31 Page:156-167
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Biard Lucie¹²,Cheng Bin¹,Manji Gulam A.³,Lee Shing M¹

Affiliation:

1. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA

2. INSERM U1153 team ECSTRRA, Université de Paris, Paris, France

3. Division of Medical Oncology, Columbia University Irving Medical Center, and New York Presbyterian Hospital, Herbert Irving Pavilion, New York, NY, USA

Funder

the American Cancer Society

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543406.2020.1814796

Reference18 articles.

1. Sample size formulae for the Bayesian continual reassessment method

2. Sequential Designs for Phase I Clinical Trials with Late-Onset Toxicities

3. Statistical Methods for Dose-Finding Experiments

4. Drug development in oncology: classical cytotoxics and molecularly targeted agents

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimands in Oncology Early Clinical Development: Assessing the Impact of Intercurrent Events on the Dose-Toxicity Relationship;Statistics in Biopharmaceutical Research;2023-12-18

2. Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression;Statistics in Medicine;2022-10-19

3. A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations;Clinical Cancer Research;2022-05-12

4. A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors;Clinical Cancer Research;2021-07-28

5. Seamless phase I/II design for novel anticancer agents with competing disease progression;Statistics in Medicine;2021-07-02